Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

ators on a submission to gain regulatory approval for Gleevec as adjuvant treatment for GIST."

Following the recommendation of a data monitoring committee, the study will be closed and patients in the study who are currently being treated with placebo may choose to receive one year of Gleevec.

In the study, patients were randomized to one of two treatment arms. Neither the patients nor physicians knew which treatment the patients were receiving. One patient group received Gleevec at a dose of 400 milligrams per day for one year, while the second group received placebo for one year. According to the study design, patients who developed a recurrence of their cancer while on a study therapy were unblinded to their treatment assignment. Those receiving placebo subsequently received Gleevec, while those already given Gleevec continued with this therapy but at a higher dose. Study results will be presented at a forthcoming scientific meeting.

Gastrointestinal stromal tumors (GIST) belong to a group of cancers known as soft tissue sarcomas that usually arise from the intestinal tract, with the most common site being the stomach followed by the small intestine. The incidence of GIST is estimated to be 4,500-6,000 new cases per year in the US (15-20 cases per million population), of which more than 90% are kit-positive.

Investigators in the NCI study reported that Gleevec therapy was well tolerated by most patients, with side effects similar to those observed in other clinical trials with Gleevec. These include nausea, diarrhea and swelling (edema). Information on more than 600 patients enrolled in the study was used in the analysis.

About Gleevec

Gleevec(R) (imatinib mesylate) is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). The effectiveness of Gleevec in GIST is based on objective response rate. There are no controlled trials demon
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:7/28/2015)... , July 28, 2015 The Physician-Patient ... patient safety fundraising campaign, " Surviving Your Hospital Stay ... the care they deserve! None of these patients went ... (Founder and Executive Director, PPAHS) referring to the ... the National Coalition to Promote Continuous Monitoring of ...
(Date:7/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/mp95jv/global_hearing ) ... Hearing Aids Market 2015-2019" report to their ... market to grow at a CAGR of 4.68% ... such as changing demographics and high prevalence of ... has witnessed immense technological advances. These factors, combined ...
(Date:7/28/2015)... CONSHOHOCKEN, Pa. , July 28, 2015 ... the keynote address at Good Neighbor Pharmacy,s 2015 ... 29 to Aug. 1 in Las Vegas, Nev. ... on CNN,s television-show, "Somebody,s Gotta Do It," and Discovery Channel,s, ... country to celebrate the nation,s  "unsung heroes" – people whose ...
Breaking Medicine Technology:Surviving Your Hospital Stay: Physician-Patient Alliance for Health & Safety Launches Fundraising for Patient Safety 2Global Hearing Aids Market 2015-2019 with G N Store Nord, Sonova Holdings & William Demant Dominating 2Mike Rowe to Address Community Pharmacists at ThoughtSpot 2015 2
... Inc. announces the sale of its skin cancer business ... SRT 100 superficial radiotherapy treatment system. Since TOPEX received ... worldwide at hospital radiation oncology centers, dermatology and veterinary ... low energy superficial radiotherapy system provides patients an alternative ...
... DIEGO, Aug. 18 Aethlon Medical, Inc. (OTC Bulletin ... therapeutic filtration devices to address infectious disease and cancer, ... with GVK Biosciences (GVK BIO) to expand the opportunity ... three to five new clinical centers in India.  The ...
Cached Medicine Technology:TOPEX Sells Skin Cancer Business Operations to SENSUS Healthcare 2Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs 2Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs 3Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs 4Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs 5
(Date:7/29/2015)... ... July 29, 2015 , ... The New Foundation AZ ... will by the end will cost the 501(c) organization nearly $1 million, will both ... requirements. , “We took it down to the studs,” said Geraldine Leary, the ...
(Date:7/29/2015)... ... July 29, 2015 , ... HealthPostures ( ... a partnership with 247Ergo, an ergonomics specialty firm. Purpose of the partnership is ... the companies undertake could improve worker mobility, functionality and fitness levels. , ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... the first dermatologist in Sarasota to be chosen by the manufacturer to offer ... offers the first injectable, non-invasive way to treat and eliminate double chin fat,” ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... which Breckheimer oversees. In her role, Powers is responsible for driving growth and ... announcement, Breckheimer commented, “Gina’s track record as an effective leader within the ITW ...
(Date:7/28/2015)... City, NY (PRWEB) , ... July 29, 2015 ... ... honors Susan Bentley as a 2015-2016 inductee into its VIP ... leadership in healthcare. NAPW is the nation's leading networking organization exclusively for professional ...
Breaking Medicine News(10 mins):Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 2Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 3Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 3Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 2Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 3Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 2Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 3Health News:National Association of Professional Women Inducts Susan Bentley, Owner of Women's Wellness Options, Into its VIP Woman of the Year Circle 2
... Universal Benefit Plans and subsidiary company Universal ... provide Massachusetts nonprofits with a cost-effective, convenient alternative ... Plans administering their employee benefits as Broker of ... access to Universal Dental Plan,s network of dentists ...
... 6, 2009 /PRNewswire-FirstCall/ - IMRIS Inc. (TSX: IM) ... secured its first order in Australia for its ... in the Asia-Pacific region. The Canberra Hospital has ... intraoperative suite as part of a larger Australian ...
... middle age, study says , , TUESDAY, Jan. 6 (HealthDay News) ... painfully obvious, nutrition experts have been divided over whether cutting ... sometimes boomerang, triggering binge eating and weight gain. , But, ... particularly as you age. , Publishing in the current issue ...
... Study Uses Intego(TM) PET Infusion System to Compare ... MEDRAD, Inc., has signed a research agreement with ... imaging with the MEDRAD Intego(TM) PET Infusion System. ... to more precisely control the radioactive dose delivered ...
... /PRNewswire/ -- Akerman Senterfitt, one ... of the top 100 firms in the U.S., today ... audiocast under the auspices of the American Health Lawyers ... Organizations (PSOs) and issues concerning privilege and confidentiality. The ...
... resolution is to stop smoking: Over 60 million Americans want ... Obama JUPITER, Fla., Jan. 6 , ... related diseases claim an estimated 438,000 lives per year, including ... result of second-hand smoke. Cigarette-related deaths kills more people ...
Cached Medicine News:Health News:Universal Benefit Plans and Universal Dental Plan Announce Joint Outreach Initiative to Aid Massachusetts Nonprofits 2Health News:It Pays to Eat Less as You Age 2Health News:MEDRAD Sponsors PET Research with University of Zurich 2Health News:MEDRAD Sponsors PET Research with University of Zurich 3Health News:MEDRAD Sponsors PET Research with University of Zurich 4Health News:Akerman Senterfitt Hosts National Panel Discussion on Patient Safety Organizations 2Health News:Akerman Senterfitt Hosts National Panel Discussion on Patient Safety Organizations 3Health News:Why Are So Many Americans Wearing Gold Earrings on their Right Ear? 2
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
12mm Blades, Maximum Spread 18mm, Spring Action, Wire - Pediatric; in stainless steel...
15mm Open Blades, 28mm Maximum Spread; Available in small(S) and large (L), in stainless steel....
7mm Cross Hairs; Available in 4.5mm to 7.0mm in 0.5mm increments; Ring depth available from 2 to 4mm in 0.5mm increments.; in stainless steel....
Medicine Products: